Genomics Innovation Alliance
The Genomics Innovation Alliance (GIA) is a key resource within Scotland's research and clinical community. GIA's mission is to advance our understanding and application of “omics” -initially genomics - in disease, thereby enhancing patient outcomes, improving efficiencies for NHS Scotland, and positioning Scotland as a global leader. Our alliance brings together key members from NHS Scotland, University of Glasgow, The Living Laboratory at Glasgow, and the CRUK Scotland Institute/Centre.
Working with NHS GGC, our forthcoming assays will be ISO15189-accredited, ensuring stringent quality standards for both clinical and research applications.
We invite collaboration from private industry, diagnostic labs (including NHS Scotland), and researchers engaged in clinical trials, all dedicated to leveraging ‘omic’ technology to advance patient health.
For potential clients in both research and clinical domains, GIA offers two cancer panel assays available now for research purposes.
Explore GIA Assays
We have two human cancer panel assays available. See the genes and classes of variants covered by the Cancer Plus and Precision-Panc next-generation sequencing panels:
Future GIA Assays
GIA leads the development, validation, and accreditation of “omic” based assays for clinical and research use. For its first assay in its translation pipeline, GIA is aggressively pursuing an accredited Solid Tumour Pan Cancer Somatic Assay.
We are working towards offering other “omic” assays.
